
Can you inherit Polycystic Ovarian Syndrome? Understanding the genetic linkage behind PCOS
Let's uncover the facts behind hereditary fertility issues and empower women across generations with the awareness of PCOS.
Why PCOS Matters Across Generations?
Polycystic Ovary Syndrome (PCOS) affects every aspect of a woman's life: metabolism, hormones, appearance, and fertility. It's not just an individual diagnosis, it can even tend to go on from one generation to the next. Research findings suggest that 4 out of 10 women who have a mother or aunt diagnosed with this endocrine female condition are at a significantly higher risk of getting PCOS themselves.
Hereditary Risk: Daughters of women with PCOS are six times more likely to develop the condition themselves (source: Human Reproduction Update)
Underdiagnosed: Up to 70% of women with PCOS remain undiagnosed, mistaking symptoms for 'bad periods' (WHO)
The Triple Threat: Obesity, Hirsutism, and Infertility
PCOS manifests in visible and invisible ways—some women struggle with weight, others with excess hair, and many with difficulty conceiving.
1. Obesity & Metabolic Risks: Among Indian women with PCOS,
32% are overweight and 11% obese under WHO cut-offs
43% obese using Asian BMI standards (source: JAMA Network Open)
2. Hirsutism (Unwanted Hair Growth):
70–80% of women with PCOS experience hirsutism compared to 5–10% in the general population (Journal of Clinical Endocrinology & Metabolism).
3. Infertility's Hidden Toll:
Almost 1 in 10 women are diagnosed with PCOS. It actively contributes to approximately 30–50% of infertility cases (ASRM).
Most of these symptoms surface over a period of time. They are over and above the symptoms of painful periods that are non-negotiable in most cases.
Diagnosis Delays & How to Avoid Them?
The risk of PCOS is hereditary, but poor lifestyle choices fuels its fire. Excess weight, sedentary habits, and insulin resistance worsen symptoms and reproductive outcomes. While your metabolic legacy can set the stage for PCOS to be triggered, healthy choices can still rewrite the story.
Women report symptoms 7–10 years before a correct PCOS diagnosis, often because cramps and weight gain are dismissed as 'normal' . Misguided treatments—like magical herbal concoctions from village hakims—delay proper care and deepen frustration. Don't wait for a 'miracle cure'—demand medical answers.' Too many women get lost in myths:
'It's just teenage acne.'
'You'll outgrow the cramps.'
'Diet pills will solve it.'
Early signs to watch for: irregular periods, severe cramps, sudden weight gain, excess hair, and skin tags. Tracking cycles and symptoms on an app can provide clarity when consulting a doctor.
Action Plan: Five Steps To Manage Risk of PCOS
Get Screened: If someone in your family also has irregular cycles or infertility, schedule a PCOS work-up by age 25 .
Track Your Cycle: Use apps to log periods, moods, and symptoms—insight is empowerment.
Tackle Weight Thoughtfully: Even 5–10% weight loss improves ovulation and hormone balance.
Address Hair & Skin: Medical hair-removal and dermatology consultations can manage hirsutism and acne.
Lean on Experts: Endocrinologists and fertility specialists who offer personalised care to facilitate early detection and proper management.
Can Early Intervention Prevent PCOS?
'Polycystic Ovary Syndrome (PCOS) is a multifaceted condition that not only affects hormonal balance but also has significant implications for fertility,' says Dr. Prachi Banera, Senior Fertility Specialist at Birla Fertility & IVF.
'Early diagnosis and a personalized treatment plan are crucial to ensure comprehensive care that addresses both the physical and emotional aspects of PCOS early on in life. Our dedicated PCOS Clinic provides personalised treatment plans, to effectively help women take control of their reproductive health.'
Birla Fertility & IVF offers a dedicated PCOS Clinic that provides personalised treatment plans, including tailored diet and nutritional guidance, to effectively manage PCOS and improve overall well-being.
When Should You Consult a Fertility Expert?
Recognising the right time to seek professional help can make a significant difference in managing PCOS and its impact on fertility. Consider consulting a fertility specialist if you experience:
Irregular or absent menstrual cycles: This may indicate ovulatory dysfunction, a common issue in PCOS.
Difficulty conceiving after 6-12 months of unprotected intercourse: Especially if you're under 35 and have been trying for a year, or over 35 and have been trying for six months.
Symptoms of hyperandrogenism: Such as excessive hair growth, acne, or hair thinning.
Early consultation allows for timely intervention, which can include lifestyle modifications, medical treatments, or assisted reproductive technologies, depending on individual needs.
Knowledge is power!
Hereditary fertility challenges don't diminish the beauty of motherhood - they deepen it. By breaking myths and sharing knowledge, daughters and mothers can transform burdens into bridges of understanding and support.
By breaking the silence around hereditary fertility issues and tackling myths head-on, daughters and mothers can foster healthier futures in the long run. Share this article with the women you love, start the conversation today, and celebrate the true beauty of womanhood - in all its strength, diversity, and resilience.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
an hour ago
- Business Standard
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.


Economic Times
2 hours ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'


NDTV
2 hours ago
- NDTV
Idli vs Moong Chilla: Which Breakfast Actually Helps With Weight Loss
When you are trying to lose weight, even everyday decisions like what to eat for breakfast can feel unnecessarily complicated. You want something that is filling but not calorie-heavy. Something that tastes good but is also healthy. And most importantly, a breakfast that does not leave you hungry an hour later. The good news is that Indian breakfasts come with plenty of comforting options, but some dishes work better than others when weight loss is your priority. Two popular contenders in this space are idlis and moong chillas. Both sound healthy, but which one actually supports your weight goals better? If you often find yourself torn between the two, here is what you should know before your next breakfast. Also Read: 11 Desi Recipes To Try For Weight Loss Diet - For Breakfast, Lunch And Dinner Nutrition Comparison: Idli vs Moong Chilla One plain idli contains around 35 to 40 calories. It is low in fat and easy to digest, but primarily consists of carbohydrates since it is made using rice and urad dal. In contrast, a single moong chilla has around 120 to 130 calories. While that may sound like more, it also offers protein and dietary fibre, which help you stay full for longer. For those focusing on weight loss, moong chilla is a better pick. The protein helps control hunger, and the fibre slows digestion, both of which play key roles in managing cravings. Idlis are not a bad choice either, but they might not be as satisfying unless paired with something substantial like sambar. Which Keeps You Full Longer? If your goal is to stay full until lunch, moong chilla has the upper hand. According to Nutritionist Rashi Chowdhary, dals and dal-based batters take longer to digest, which means fewer mid-morning hunger pangs. The high protein and fibre in moong chilla also help regulate blood sugar levels, preventing sudden spikes and crashes that often trigger snacking. Idlis, though light and easy on the stomach, have a high glycaemic index and digest more quickly. So, if you eat them alone without a side like sambar, you might be rummaging through your snack drawer sooner than expected. Gut Health: Which Is Easier On The Stomach? This is where idlis come out ahead. Thanks to the fermentation process, idlis contain beneficial bacteria that support gut health and aid digestion. Their soft, fluffy texture also makes them gentle on the stomach, particularly helpful for those recovering from acidity or sensitive digestion. They are also less likely to cause bloating. On the other hand, moong chilla can sometimes lead to discomfort if your gut is not used to lentils, especially if the dal has not been soaked properly. Nutritionist Rashi Chowdhary advises soaking dals for at least four to six hours to soften their outer layer and ease digestion. Soaking not only keeps the nutrients intact but also reduces gas and bloating. That said, if lentils are a regular part of your diet, moong chilla should not cause any trouble. Weight Loss Verdict: Idli or Moong Chilla? If your main goal is managing weight and reducing cravings, moong chilla is the stronger option. It has higher amounts of protein and fibre, which help with satiety, making it a solid choice for anyone following a calorie-controlled diet. You can also boost its nutritional profile by pairing it with curd or mint chutney. That said, idlis are not off the table either. When made with ragi or oats and eaten with sambar, they become a light and gut-friendly meal. The key is to alternate between the two based on your energy needs and what your body feels like on a given day. It ultimately depends on your fitness goals and schedule. Also Read: 10 Mistakes To Avoid When You Are On Weight Loss Diet Tips To Make Your Moong Chilla Healthier 1. Add Vegetables To The Batter Moong chillas are typically plain, but you can enrich them with vegetables like grated carrots, spinach, cabbage, or capsicum. This adds fibre and micronutrients without increasing the calorie count. 2. Cook With Minimal Fat Use a cast-iron or non-stick pan, and brush it lightly with ghee. Avoid using too much oil; a small amount is enough to cook it through. 3. Pair It With Protein-Rich Curd Adding a bowl of curd on the side can balance the meal and promote digestion, thanks to the probiotics in curd. 4. Skip The Paneer Stuffing While paneer is a good protein source, it also increases the calorie count significantly. If weight loss is your goal, avoid adding paneer to your chilla. 5. Choose Whole Green Moong Whole green moong has more fibre compared to yellow moong dal. It takes slightly longer to soak but will keep you full for longer and adds a nutty depth of flavour. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your doctor for more information. NDTV does not claim responsibility for this information. Advertisement About Nikita Nikhil Meet Nikita, a passionate soul with an insatiable love for two things in life: Bollywood and food! When she's not indulging in binge-watching sessions, Nikita can be found behind the lens capturing moments or expressing her creativity through painting. For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube. Tags: Idli Moong Chilla Weight Loss Breakfast Show full article